Literature DB >> 23910161

[Phenylketonuria: new treatments].

F Feillet1, C Bonnemains.   

Abstract

Low phenylalanine diet has been the key treatment of phenylketonuria for more than 50years, allowing efficient management of thousands of PKU patients to date. However, non-compliance exists, mainly after adolescence. A medication for PKU received approval in Europe in 2009 (sapropterine dihydrochloride or Kuvan(®)) and can benefit to patients responsive to this drug. Other treatment options are available in some countries (glycomacropeptides, large neutral amino acids) or are currently under investigation (phenylalanine ammonia lyase, chaperones molecules, gene therapy).
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23910161     DOI: 10.1016/j.arcped.2013.06.021

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

1.  Unmet needs in PKU and the disease impact on the day-to-day lives in Brazil: Results from a survey with 228 patients and their caregivers.

Authors:  Ana Maria Martins; Andre Luiz Santos Pessoa; Andrea Amaro Quesada; Erlane Marques Ribeiro
Journal:  Mol Genet Metab Rep       Date:  2020-07-22

2.  Development of a Whole Blood Paper-Based Device for Phenylalanine Detection in the Context of PKU Therapy Monitoring.

Authors:  Robert Robinson; Liam Wong; Raymond J Monnat; Elain Fu
Journal:  Micromachines (Basel)       Date:  2016-02-15       Impact factor: 2.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.